Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 39 - Medicinal preparations containing antigens or antibodies
Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
10/2013
10/23/2013EP2651438A1 Vaccine
10/23/2013EP2651437A1 Mycobacterium antigenic composition
10/23/2013EP2651436A1 Mycobacterium antigenic composition
10/23/2013EP2651435A1 Method for suppressing an immune response
10/23/2013EP2651434A2 Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
10/23/2013EP2651402A1 Process for preparing nanoparticles of two polyamino acids of opposite charge, one of the two of which is in charge surplus
10/23/2013EP2651394A1 Nanoparticles comprising at least one active agent and at least two polyelectrolytes
10/23/2013CN103370411A Adenovirus serotype 26 and serotype 35 filovirus vaccines
10/23/2013CN103370333A Highly immunogenic HIV P24 sequences
10/23/2013CN103370081A Selection and treatment of subjects
10/23/2013CN103370080A Antibodies that bind to lysyl oxidase-like 2 (LOXL2) and methods of use therefor
10/23/2013CN103370079A Herpesvirus of turkeys vectored vaccine against avian influenza in poultry
10/23/2013CN103370078A Novel European PRRSV strain
10/23/2013CN103370077A Commercial scale process for production of PRRSV
10/23/2013CN103370076A Methods for treating hair loss disorders
10/23/2013CN103370052A Nanoparticles comprising at least one active agent and at least two polyelectrolytes
10/23/2013CN103369973A Novel use of maltotriosyl transferase
10/23/2013CN103361377A Method for generating HPV6 L1 (Human Papillomavirus) proteins by using hansenula polymorpha expression system
10/23/2013CN103361364A Eimeria tenella eIF3d gene and application thereof
10/23/2013CN103361293A Pathogenic strain for Scophthalmus maximus and application thereof
10/23/2013CN103361280A Method for generating HPV11 L1 (Human Papillomavirus) by using hansenula polymorpha expression system
10/23/2013CN103360498A 一种抗鸡传染性法氏囊病的重组蛋白亚单位疫苗 An anti-IBD recombinant protein subunit vaccines
10/23/2013CN103360496A Anti-EphB4 antibodies and methods of using these antibodies
10/23/2013CN103360494A Completely anti-CD20 human monoclonal antibody and application thereof
10/23/2013CN103360493A Cross-reactive and bispecific anti-IL 17A/F antibodies
10/23/2013CN103360491A Anti-helicobacter pylori FlaA protein antibody IgY, preparation method and application thereof
10/23/2013CN103360483A Recombinant allergen with reduced IgE binding but undiminished T-cell antigenicity
10/23/2013CN103360479A Cow's milk staphylococcus aureus Efb protein and its preparation method and application thereof
10/23/2013CN103360477A Modified hepatitis C virus (HCV) Type 4 envelope E2 protein and application thereof
10/23/2013CN103360476A Modified hepatitis C virus (HCV) Type 2a envelope E2 protein and application thereof
10/23/2013CN103360475A Modified hepatitis C virus (HCV) Type 5 envelope E2 protein and application thereof
10/23/2013CN103360474A Modified hepatitis C virus (HCV) Type 3a envelope E2 protein and application thereof
10/23/2013CN103360473A Modified hepatitis C virus (HCV) Type 6 envelope E2 protein and application thereof
10/23/2013CN103360465A HLA-A*0201 restricted CTL epitope of cytoplasmic polyadenylation element binding proteins (CPEBs) 4 and application thereof
10/23/2013CN103357011A Pharmaceutical composition and composite burn cream for treating burns and scalds and preparation method thereof
10/23/2013CN103357010A Vaccine composition
10/23/2013CN103357009A Application of Hemokinin-1 in preparation of vaccine adjuvant
10/23/2013CN103357008A Novel vaccine adjuvant based on bacillus calmette guerin-polysaccharide nucleic acid and application of novel vaccine adjuvant
10/23/2013CN103357007A Immunogenic compositions and methods of use
10/23/2013CN103357006A Extractive and preparation containing same
10/23/2013CN103357005A Live attenuated rotavirus vaccine for oral administration
10/23/2013CN103357004A Method for raising utilization rate of avian influenza antigen
10/23/2013CN103357003A Vaccine
10/23/2013CN103357002A Liquid vaccines for multiple meningococcal serogroups
10/23/2013CN103357001A Preparation method of tumour antigen
10/23/2013CN103356511A Protein drug transdermal drug delivery patch
10/23/2013CN102793915B Production method of acellular pertussis vaccine
10/23/2013CN102626515B Process for activating Haemophilus influenzae type b (Hib) polysaccharide conjugate vaccine
10/23/2013CN102443063B Anti-TNFalpha humanized Fab, humanized antibody and its application
10/23/2013CN102233132B Application of VEGF acceptor fusion proteins in preparation of drugs for inhibiting growth of ocular surface neovascularization
10/23/2013CN102140430B Mouse-typhus salmonella gene-deletion mutant strain without containing resistance marks, vaccine and application thereof
10/23/2013CN101896197B Polysaccharide immunogens from clostridium difficile
10/23/2013CN101808658B Cell-penetrating peptides and use thereof bonded to biomolecules with therapeutic action
10/23/2013CN101646690B Antibodies to il-17a
10/23/2013CN101588815B Prostate kallikrein allergen
10/22/2013US8563707 Compositions and methods for detection of hepatitis A virus nucleic acid
10/22/2013US8563706 Efficient cell culture system for hepatitis C virus genotype 1A and 1B
10/22/2013US8563700 Synergistic effects
10/22/2013US8563699 Anthrax and small Pox replikins and methods of use
10/22/2013US8563696 Antibody specifically binding to c-Met
10/22/2013US8563694 Fully human antibodies to BTLA
10/22/2013US8563693 Method of treating human immunodeficiency virus infection in a mammal comprising administering heparin-activated antithrombin III
10/22/2013US8563692 Interferon-antibody fusion proteins demonstrating potent apoptotic and anti-tumor activities
10/22/2013US8563684 Tumor antigen protein SART-3 and tumor antigen peptides thereof
10/22/2013US8563520 Treatment of ocular disease with inhibitors of alpha2 macroglobulin protein
10/22/2013US8563511 Treatment of pulmonary hypertension using an agent that inhibits a tissue factor pathway
10/22/2013US8563506 Compositions and methods for treating aids or cancer by inhibiting the secretion of microparticles
10/22/2013US8563476 Anti-CXCL9, anti-CXCL10, anti-CXCL11, anti-CXCL13, anti-CXCR3 and anti-CXCR5 agents for inflammatory disorders
10/22/2013US8563249 Receptor gene screening for detecting or diagnosing cancer
10/22/2013US8563008 Polynucleotides and polypeptides involved in gestational malaria, and biological applications
10/22/2013US8563007 Immunogenic compositions for the prevention and treatment of meningococcal disease
10/22/2013US8563006 Immunogenic compositions for the prevention and treatment of meningococcal disease
10/22/2013US8563005 Actinobacillus suis antigens
10/22/2013US8563004 Yersinia spp. polypeptides and methods of use
10/22/2013US8563003 Method for the treatment of malignant and infectious chronic diseases
10/22/2013US8563002 Recombinant RSV antigens
10/22/2013US8563001 Multicomponent immunogenic composition for the prevention of beta-hemolytic streptococcal (BHS) disease
10/22/2013US8563000 Melanocortin receptor ligands modified with hydantoin
10/22/2013US8562999 Formulations which stabilize and inhibit precipitation of immunogenic compositions
10/22/2013US8562998 Targeting of antigen presenting cells with immunonanotherapeutics
10/22/2013US8562997 Methods of treating acute myeloid leukemia by blocking CD47
10/22/2013US8562996 RSV-specific binding molecules and means for producing them
10/22/2013US8562995 Neoplasm specific antibodies and uses thereof
10/22/2013US8562994 Human-murine chimeric antibodies against respiratory syncytial virus
10/22/2013US8562993 Methods for treating GI syndrome and graft versus host disease
10/22/2013US8562992 Immunoglobulin variants and uses thereof
10/22/2013US8562991 Antibody molecules that bind to IL-6 receptor
10/22/2013US8562990 Method of treating psoriatic arthritis with an IL-6 receptor antibody
10/22/2013US8562989 Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer
10/22/2013US8562988 Strategies for improved cancer vaccines
10/22/2013US8562987 Humanized anti-CD70 binding agents and uses thereof
10/22/2013US8562986 Engineered anti-alpha V-integrin hybrid antibodies
10/22/2013US8562985 Antibodies to c-Met
10/22/2013US8562984 Methods of treatment using anti-IL-20 antibodies
10/22/2013US8562970 Modified CEA/B7 vector
10/22/2013CA2580981C Stabilized human igg4 antibodies
10/22/2013CA2566199C Delivery of as-oligonucleotide microspheres to induce dendritic cell tolerance for the treatment of autoimmune type 1 diabetes
10/22/2013CA2522957C Compositions and methods for the therapy of inflammatory bowel disease
10/22/2013CA2497884C Therapeutic human anti-il-1r1 monoclonal antibody
10/22/2013CA2473526C Polyalkylene polymer compounds and uses thereof
1 ... 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 ... 1823